MedTrace Logo

Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal Carcinoma

NCT07789158 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 269

Last updated 2026-08-27

No results posted yet for this study

Summary

To evaluate whether the 2-year local failure-free survival (LRFFS) in Cohort 1 patients with AJCC/UICC 8th edition stage IB-II nasopharyngeal carcinoma who achieved EBV-DNA = 0 after induction chemotherapy and had MRI assessment of complete response (CR) or partial response (PR) ≥50% is non-inferior when treated with reduced-dose IMRT (59.4 Gy/27 fractions) compared to standard-dose IMRT (66.0 Gy/30 fractions).

Conditions

  • Nasopharyngeal Carcinoma (NPC)

Interventions

RADIATION

reduced dose group

59.4 Gy/27F

RADIATION

Standard Dose Group

66 Gy/30F

OTHER

concurrent chemoradiotherapy

66.0-70.4 Gy/30-32F + cisplatin 80 mg/m² q3w×2

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Xiayun He · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2031-08-31
Completion
2031-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07789158 on ClinicalTrials.gov